Bayer, the powerful pharmaceutical group and a German chemist, has announced this Thursday that it plans to eliminate 12,000 jobs around the world until the end of 2021, the majority of them in Germany. The severe cropping of the template is part of a plan to improve the group’s efficiency and will take place in the business of producing crops and in the corporate functions general.
The figure of 12,000 layoffs equivalent to almost 10% of the workforce of the company in all the world, formed currently by 118.200 employees. About 4,100 jobs will be cut in the seed business, and a further 6,000 in corporate functions and on platforms from several countries.
MORE INFORMATION
The purchase of Monsanto by Bayer loses value When Bayer engulfed Monsanto Bayer sold to Basf part of your business agrochemical by 5.900 million euros to be able to buy Monsanto
The group, which has its headquarters in the city of Leverkusen, said that the priority objective is to increase the productivity and the profitability and increase the competitiveness of the group, in addition to generate annual contributions of 2,600 million euros, including the anticipated synergies of the acquisition of Monsanto in 2022. Part of this money will be reinvested in the business are considered strategic for the group.
Among other measures, the company intends to withdraw from the business of veterinary medicine. He also wants to sell the brands Coppertone (sunscreens), and Dr. Scholl (foot care) and its share Klasbahis of the 60 percent in the German provider of facility services chemical Currenta , which operates three chemical plants in Germany.
“These changes are necessary and will establish new bases for Bayer, will allow you to improve your performance and your flexibility,” said Werner Baumann, the ceo of the group.
According to information of the German economic news, Bayer is engaged in a struggle with several fronts. In the united States, after the acquisition of Monsanto, the group has faced numerous lawsuits related to the glyphosate. The plaintiffs allege that the american company Monsanto, which was acquired by Bayer, sold glyphosate, a known carcinogen, and you have not provided sufficient information on its harmfulness.
Bayer has firmly rejected these allegations, even so the shares of the company fell sharply by these accusations. Late last month, the u.s. subsidiary faced 9,300 cases related to the use of glyphosate. But Bauman, the ceo of the group, has continued to place your trust in the integration of Monsanto and, although it acknowledged that there could be more demands, reiterated that Bayer “will defend itself with all available means”.
According to the newspaper Handelsblatt, the committee of Bayer had already expressed his concern about the employment situation in the company in October and had asked security, long-term beyond 2020.
